Dr. Anna Groover is a Senior Scientist in the Translational Sciences group at BioMed Valley Discoveries, where she manages day-to-day clinical operations for clinical trials involving BVD-523, a selective, reversible, ERK1/2 inhibitor.
Anna joined BioMed Valley Discoveries after completing her PhD in anatomy and cell biology at the University of Kansas Medical Center. She received a BS degree in biology from Baylor University.